199 related articles for article (PubMed ID: 34936143)
1. Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections.
Roth RS; Masouridi-Levrat S; Giannotti F; Mamez AC; Glambedakis E; Lamoth F; Bochud PY; Erard V; Emonet S; Van Delden C; Kaiser L; Chalandon Y; Neofytos D
Mycoses; 2022 Feb; 65(2):199-210. PubMed ID: 34936143
[TBL] [Abstract][Full Text] [Related]
2. When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?
Roth RS; Masouridi-Levrat S; Giannotti F; Mamez AC; Morin S; van Delden C; Chalandon Y; Neofytos D
Mycoses; 2022 Nov; 65(11):1061-1067. PubMed ID: 35815918
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation.
Glampedakis E; Roth R; Masouridi-Levrat S; Chalandon Y; Mamez AC; Giannotti F; Van Delden C; Neofytos D
J Fungi (Basel); 2021 Sep; 7(10):. PubMed ID: 34682233
[TBL] [Abstract][Full Text] [Related]
4. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009).
Klingspor L; Saaedi B; Ljungman P; Szakos A
Mycoses; 2015 Aug; 58(8):470-7. PubMed ID: 26152371
[TBL] [Abstract][Full Text] [Related]
6. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm.
Chan SY; Hughes RM; Woo K; Perales MA; Neofytos D; Papanicolaou G
Med Mycol; 2020 Nov; 58(8):1029-1036. PubMed ID: 32171012
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Bow EJ; Vanness DJ; Slavin M; Cordonnier C; Cornely OA; Marks DI; Pagliuca A; Solano C; Cragin L; Shaul AJ; Sorensen S; Chambers R; Kantecki M; Weinstein D; Schlamm H
BMC Infect Dis; 2015 Mar; 15():128. PubMed ID: 25887385
[TBL] [Abstract][Full Text] [Related]
9. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
10. Antifungal prophylaxis with fluconazole in allogeneic stem cell transplantation recipients who had prior invasive aspergillosis with subsequent complete resolution by computed tomography.
Akahoshi Y; Kimura SI; Gomyo A; Hayakawa J; Tamaki M; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Nakasone H; Kako S; Kanda Y
Infect Dis (Lond); 2018 Apr; 50(4):280-288. PubMed ID: 29087731
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience.
Neofytos D; Treadway S; Ostrander D; Alonso CD; Dierberg KL; Nussenblatt V; Durand CM; Thompson CB; Marr KA
Transpl Infect Dis; 2013 Jun; 15(3):233-42. PubMed ID: 23432974
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and clinical characteristics of invasive mould infections: A multicenter, retrospective analysis in five Asian countries.
Rotjanapan P; Chen YC; Chakrabarti A; Li RY; Rudramurthy SM; Yu J; Kung HC; Watcharananan S; Tan AL; Saffari SE; Tan BH
Med Mycol; 2018 Feb; 56(2):186-196. PubMed ID: 28525619
[TBL] [Abstract][Full Text] [Related]
14. Antifungal Treatment Duration in Hematology Patients With Invasive Mold Infections: A Real-life Update.
Portillo V; Ragozzino S; Stavropoulou E; El-Khoury C; Bochud PY; Lamoth F; Khanna N; Neofytos D
Open Forum Infect Dis; 2024 May; 11(5):ofae201. PubMed ID: 38756760
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation.
Linke C; Ehlert K; Ahlmann M; Fröhlich B; Mohring D; Burkhardt B; Rössig C; Groll AH
Mycoses; 2020 Feb; 63(2):172-180. PubMed ID: 31661569
[TBL] [Abstract][Full Text] [Related]
16. A Single-Center, Open-Label Trial of Isavuconazole Prophylaxis against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Stern A; Su Y; Lee YJ; Seo S; Shaffer B; Tamari R; Gyurkocza B; Barker J; Bogler Y; Giralt S; Perales MA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1195-1202. PubMed ID: 32088367
[TBL] [Abstract][Full Text] [Related]
17. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients.
Bhatti Z; Shaukat A; Almyroudis NG; Segal BH
Mycopathologia; 2006 Jul; 162(1):1-15. PubMed ID: 16830186
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
19. Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
Roth RS; Masouridi-Levrat S; Chalandon Y; Mamez AC; Giannotti F; Riat A; Fischer A; Poncet A; Glampedakis E; Van Delden C; Kaiser L; Neofytos D
Open Forum Infect Dis; 2022 Jan; 9(1):ofab596. PubMed ID: 34993259
[TBL] [Abstract][Full Text] [Related]
20. Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients.
Bow EJ
Med Mycol; 2005 May; 43 Suppl 1():S277-87. PubMed ID: 16110821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
